📷 Image: Wikimedia Commons / Vyacheslav Argenberg
Health
Maharashtra FDA Seizes FDC Enerzal Stock Over Alleged Misbranding
✍️ scanx.trade
🗓 31 Aug 2026, 02:18 PM
👁 3
The Maharashtra Food and Drug Administration has confiscated stock of the drug FDC Enerzal, citing misbranding violations, according to an official notice.
The Maharashtra Food and Drug Administration (FDA) announced that it has seized a consignment of the pharmaceutical product FDC Enerzal after detecting alleged misbranding. The regulatory agency said the batch did not comply with labeling norms prescribed under the Drugs and Cosmetics Act, prompting immediate action to prevent its distribution.
According to the FDA's statement, the seized stock was located at a distribution centre within the state, and the agency has issued a show‑cause notice to the manufacturer for violating labeling standards. The authorities are conducting a detailed investigation to determine the extent of the non‑compliance and to decide on further punitive measures.
The move underscores the state's ongoing efforts to tighten oversight of medicines and protect consumers from potentially misleading information. The FDA has urged pharmacies and wholesalers to verify the authenticity and labeling of all drugs before sale, reiterating its commitment to enforce strict regulatory norms.
No public health risk has been reported so far, and the agency has advised the public to continue using approved medicines while the investigation proceeds.
According to the FDA's statement, the seized stock was located at a distribution centre within the state, and the agency has issued a show‑cause notice to the manufacturer for violating labeling standards. The authorities are conducting a detailed investigation to determine the extent of the non‑compliance and to decide on further punitive measures.
The move underscores the state's ongoing efforts to tighten oversight of medicines and protect consumers from potentially misleading information. The FDA has urged pharmacies and wholesalers to verify the authenticity and labeling of all drugs before sale, reiterating its commitment to enforce strict regulatory norms.
No public health risk has been reported so far, and the agency has advised the public to continue using approved medicines while the investigation proceeds.